Results 131 to 140 of about 24,275 (247)

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This review synthesises current knowledge on gut microbiome involvement in obesity and hypertension, evaluates microbiome‐based therapeutic strategies, and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics.
Andrej Belančić, Almir Fajkić, Yusuf Ziya Sener, Ana Jelaković, Lejla Alić, Elvira Meni Maria Gkrinia, Donatella Verbanac, Bojan Jelaković   +7 more
wiley   +1 more source

Natural Products as the Modulators of Gut Microbiota: A Pool for the Development of New Treatment Against Obesity?

Food Frontiers, Volume 7, Issue 3, May 2026.
Natural compounds regulate gut microbiota by improving microbial balance and increasing probiotics, which boost short‐chain fatty acid production to alleviate insulin resistance and inflammation. Additionally, they stimulate appetite‐suppressing hormones through bile acid signaling, while inhibiting pathogenic bacteria to repair intestinal barrier ...
Hongchao Yuan, Yau‐Yuen Chan, Guang Chen, Lin Xu, Cheng Zhang, Guoyi Tang, Yibin Feng, Ning Wang   +7 more
wiley   +1 more source

Post-translational modifications of lipid-activated nuclear receptors: Focus on metabolism [PDF]

, 2017
Post-translational modifications (PTM) occur to nearly all proteins, are catalysed by specific enzymes and are subjected to tight regulation. They have been shown to be a powerful means by which the function of proteins can be modified resulting in ...
Becares Salles, N, Gage, MC, Pineda-Torra, I   +2 more
core  

Targeting of Gut Microbiota by Bioactive Peptides for the Improvement of Metabolic Diseases: A Review

Food Frontiers, Volume 7, Issue 3, May 2026.
Bioactive peptides (BPs) derived from dietary proteins modulate the gut microbiotametabolism axis by reshaping microbial composition and regulating key metabolites, including short‐chain fatty acids. BPs also enhance intestinal barrier integrity and immune homeostasis, thereby reducing inflammation.
Jiao Li, Yongchao Chen, Zhihua Li, Gang Liu, Hongmei Jiang, Jun Fang, Sujuan Ding   +6 more
wiley   +1 more source

Revisiting Parenteral Nutrition-Associated Liver Disease (PNALD) [PDF]

, 2017
Parenteral Nutrition-Associated Liver Disease (PNALD) causes progressive cholangitis which can lead to liver failure and cirrhosis especially in infants.
Pullicino, Edgar
core  

Epidemiology, Risk Factors and Pathophysiology of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: An Update

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) represent a unique clinical syndrome affecting up to 80% of PSC patients, characterised by distinct epidemiological patterns, pathophysiological mechanisms and clinical outcomes that differ substantially from either condition occurring independently ...
Luisa Bertin, Paul Henderson, Richard Pollok, Natália Queiroz, Luca Fabris, Edoardo Vincenzo Savarino, Iago Rodríguez‐Lago, Brigida Barberio   +7 more
wiley   +1 more source

Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies

MedComm, Volume 7, Issue 5, May 2026.
The mechanism of multiple signaling pathways and their related targeted inhibitors in HCC. (A) The mechanism of Ras/Raf/MEK/ERK signaling pathway and its related targeted inhibitors; (B) the mechanism of PI3K/AKT/mTOR signaling pathway and its crosstalk with other pathways and its related targeted inhibitors; (C) the mechanism of JAK/STAT signaling ...
Penghui He, Sinan Xie, Kunlin Xie, Fengwei Gao, Yunshi Cai, Yan Huang, Chang Liu, Hong Wu, Yinghao Lyu, Tian Lan   +9 more
wiley   +1 more source

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies

MedComm, Volume 7, Issue 5, May 2026.
Tumors are no longer viewed as sterile but dynamic ecosystems harboring low‐biomass intratumoral microbiota. These microbes, derived from gut, oral cavity, or circulation, shape tumorigenesis and therapy response via core mechanisms: immunomodulation (regulating T cells, macrophages), metabolic reprogramming (SCFAs, indoles, bile acids), chronic ...
Haoling Zhang, Zengkan Du, Ping Lu, Aimin Jiang, Yadong Guo, Yawei Liu, Zhijing Song, Bing Dai, Wangzheqi Zhang   +8 more
wiley   +1 more source